title: The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia.
abstract: OBJECTIVE
  Accurate quantification of BCR-ABL mRNA is of critical importance for managing patients with chronic myeloid leukemia (CML) who are receiving imatinib therapy. RNA degradation thus constitutes a potential problem for laboratories quantifying minimal residual disease (MRD). Patients' samples that take a long time to be transported from the hospital to the analyzing laboratory may be subject to RNA degradation with a corresponding loss in sensitivity and possible generation of false negative results. Recently, RNA preservation systems have been developed in order to improve RNA stability. The aim of the present study was to investigate such a system.
  
  
  METHODS
  We evaluated the performance of the PAXgene Blood RNA Kit in follow-up CML peripheral blood samples and compared the results to those from unstabilized parallel Trizol extracted samples. The different sample processing methods were evaluated by real-time polymerase chain reaction (PCR) analysis.
  
  
  RESULTS
  RNA isolated with the PAXgene system gave a superior yield per milliliter of blood than did the routine Trizol extraction method. However, although of comparable quality, the RNA did not PCR-amplify as efficiently as equal amounts of RNA from routinely processed samples. Therefore, RNA processed with the PAXgene system showed decreased sensitivity for MRD detection, resulting in false negative results. The sensitivity was comparable to that of samples processed routinely 20-30 hours after phlebotomy.
  
  
  CONCLUSIONS
  We conclude that routinely processed, i.e. unstabilized, peripheral blood that reaches the laboratory and is processed within 30 hours is preferable for MRD detection. Optimal results were achieved with fresh samples processed within 5 hours with the Trizol method. However, RNA stabilization may be useful if sample transit is expected to exceed 30 hours.
authors.affiliation: Department of Genetics and Pathology, Uppsala University Hospital, Sweden.
authors.forename: Ingrid
authors.initials: I
authors.lastname: Thörn
authors.forename: Ulla
authors.initials: U
authors.lastname: Olsson-Strömberg
authors.forename: Cecilia
authors.initials: C
authors.lastname: Ohlsen
authors.forename: Anna-Maria
authors.initials: AM
authors.lastname: Jonsson
authors.forename: Ulf
authors.initials: U
authors.lastname: Klangby
authors.forename: Bengt
authors.initials: B
authors.lastname: Simonsson
authors.forename: Gisela
authors.initials: G
authors.lastname: Barbany
mesh_terms: D005786:Gene Expression Regulation / Q000235:genetics; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood / Q000235:genetics*; D018365:Neoplasm, Residual / Q000097:blood / Q000235:genetics; D020871:RNA Stability / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics*; D011933:Reagent Kits, Diagnostic / Q000592:standards
chemical_list: D012333:RNA, Messenger; D011933:Reagent Kits, Diagnostic